Effects of previous exposure to different medications on clinical course of COVID-19 patients in Istanbul, Turkey
Running head: Chronic drug utilization and COVID-19
Ülkü Sur Ünal1,2*, Hasan Raci Yananlı2, Ömer Kays Ünal3, Yasemin Doğan Kaya4, Merve Keskin511Department of Histology and Embryology, Istanbul University School of Medicine, Istanbul, Turkey, Fikriye Güngören622Drug Discovery and Safety Master of Science Programme, Vrije University, Amsterdam, Holland Atila Karaalp233Department of Medical Pharmacology, Istanbul Saglik ve Teknoloji University School of Medicine, Istanbul, Turkey
1Uskudar Zeynep Kamil Family Health Center, Istanbul, Turkey
2Department of Medical Pharmacology, Marmara University School of Medicine, Istanbul, Turkey
3Department of Orthopaedics and Traumatology, Maltepe University School of Medicine, Istanbul, Turkey
4Sultanbeyli Jandarma Ustegmen Rahim Celik Family Health Center, Istanbul, Turkey
5Beyoglu 6th Family Health Center, Istanbul, Turkey
6Eyup Islambey Family Health Center, Istanbul, Turkey
*Corresponding author
Dr. Ülku Sur Ünal, MD, PhD candidate
Uskudar Zeynep Kamil Family Health Center, Validei Atik Mah, Eski Toptasi Cad. No: 126/2 Istanbul, Turkey
E-mail: ulkusurunal@hotmail.com
ORCID: 0000-0003-4758-4413
The authors confirm that the principal investigator for this study is Dr. Ülkü Sur Ünal, and that she had direct clinical responsibility for patients.
Keywords: COVID-19/epidemiology, pharmacoepidemiology, SARS-CoV-2, hypoglycemic agents, calcium channel blockers
Word count: 3422 (without abstract and references)
Table count: 6
Figure count: 1